What is the recommended dosage of Ponatinib?

Release date: 2026-01-20 17:41:33     Recommended: 194

Ponatinib is an oral tyrosine kinase inhibitor primarily indicated for the treatment of specific types of leukemia. It is particularly effective for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients who are resistant or intolerant to prior therapies, as well as for those with the T315I mutation. The medication must be administered strictly in accordance with the doctor’s instructions; the dosage should not be adjusted or the treatment discontinued without medical approval.

What is the recommended dosage of Ponatinib?

Usual dosage: 45 mg once daily, which can be taken with or without food.

Dosage adjustment: The dosage may be reduced to 30 mg or 15 mg based on disease progression, adverse reactions, or comorbidities (e.g., hypertension, cardiovascular diseases).

Missed dose management: If a dose is missed, it can be supplemented within 12 hours; if more than 12 hours have elapsed, skip the missed dose and take the next scheduled dose as planned.

Common Adverse Reactions of Ponatinib

High-frequency reactions: Hypertension, skin rash, abdominal pain, headache, fatigue, constipation, arthralgia.

Severe risks: Vascular occlusion (including arterial thrombosis, stroke, myocardial infarction); heart failure, abnormal liver function, pancreatitis, bleeding tendency; myelosuppression (thrombocytopenia, neutropenia).

Precautions and Contraindications for Ponatinib

Monitoring requirements:

Regular monitoring of blood pressure, complete blood count, liver function, and cardiovascular parameters is required before and during treatment.

Seek immediate medical attention if symptoms such as chest pain, dyspnea, or numbness of limbs occur.

Contraindicated populations:

Patients hypersensitive to any component of the drug.

Patients with uncontrolled hypertension, active bleeding, or severe liver impairment.

Drug interactions:

Avoid concurrent use with potent CYP3A4 inhibitors (e.g., clarithromycin) or anticoagulants, as these combinations may increase toxicity or bleeding risk.